Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS -Mutant Lung Cancer

Kitai, Hidenori, Ebi, Hiromichi, Tomida, Shuta, Floros, Konstantinos V., Kotani, Hiroshi, Adachi, Yuta, Oizumi, Satoshi, Nishimura, Masaharu +2 more·2016·Cancer Discovery
DOI 10.1158/2159-8290.cd-15-1377

Cited by (162)

Items 101–162 of 162

  1. The oncogene-dependent resistance to reprogramming unveils cancer therapeutic targets
    Kenji Ito, Kohei Nagata, Sho Ohta, Yutaka Matsuda, Tomoyo Ukai, Ichiro Yasuda, Akira Ota, Ryota Kobayashi, Mio Kabata, Nao Sankoda et al. · 2022 · Cell Reports
  2. Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer
    Yoshimura, Akihiro, Horinaka, Mano, Yaoi, Takeshi, Ono, Hisako, Itoh, Kyoko, Yamada, Tadaaki, Takayama, Koichi, Sakai, Toshiyuki · 2024 · British Journal of Cancer
  3. JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
    Kang, Di, Wang, Yanping, Lin, Yiwei, Ma, Wen Wee, Morgensztern, Daniel, Leventakos, Konstantinos, Bi, Chao, Ding, Yuli, Xiong, Jing, Yan, Man et al. · 2025 · Clinical Cancer Research
  4. Pan‐HER inhibitors overcome lorlatinib resistance caused by NRG1 / HER3 activation in ALK ‐rearranged lung cancer
    Hirokazu Taniguchi, Kazumasa Akagi, Yosuke Dotsu, Tadaaki Yamada, Sawana Ono, Erika Imamura, Hiroshi Gyotoku, Shinnosuke Takemoto, Hiroyuki Yamaguchi, Triparna Sen et al. · 2022 · Cancer Science
  5. KRASG12C inhibitor: combing for combination
    Atanu Chakraborty · 2020 · Biochemical Society Transactions
  6. Comprehensive drug response profiling and pan-omic analysis identified therapeutic candidates and prognostic biomarkers for Asian cholangiocarcinoma
    Supawan Jamnongsong, Patipark Kueanjinda, Pongsakorn Buraphat, Phuwanat Sakornsakolpat, Kulthida Vaeteewoottacharn, Seiji Okada, Siwanon Jirawatnotai, Somponnat Sampattavanich · 2022 · iScience
  7. Chemotherapy confers a conserved secondary tolerance to EGFR inhibition via AXL-mediated signaling bypass
    Mark Borris D. Aldonza, Roben Delos Reyes, Young Seo Kim, Jayoung Ku, Ana Melisa Barsallo, Ji-Young Hong, Sang Kook Lee, Han Suk Ryu, YongKeun Park, Je‐Yoel Cho et al. · 2021 · Scientific Reports
  8. Chemical Proteomics with Novel Fully Functionalized Fragments and Stringent Target Prioritization Identifies the Glutathione-Dependent Isomerase GSTZ1 as a Lung Cancer Target
    Yi Liao, Sean Chin Chan, Eric A. Welsh, Bin Fang, Luxin Sun, E. Schönbrunn, John M. Koomen, Derek R. Duckett, Eric B. Haura, Andrii Monastyrskyi et al. · 2023 · ACS Chemical Biology
  9. The KRAS signaling pathway's impact on the characteristics of pancreatic cancer cells
    Meiyan Chen, Meiyan Chen, Yuka Fu, Jingyi Zhang · 2023 · Pathology - Research and Practice
  10. MIG6 Mediates Adaptive and Acquired Resistance to ALK/ROS1 Fusion Kinase Inhibition through EGFR Bypass Signaling
    Nan Chen, Logan C. Tyler, Anh Tuan Le, Eric A. Welsh, Bin Fang, Andrew Elliott, Kurtis D. Davies, Thomas Danhorn, Gregory J. Riely, Marc Ladanyi et al. · 2023 · Molecular Cancer Therapeutics
  11. MCL1 inhibition enhances the therapeutic effect of MEK inhibitors in KRAS-mutant lung adenocarcinoma cells
    Makoto Tada, Toshiyuki Sumi, Yusuke Tanaka, Sachie Hirai, Miki Yamaguchi, Masahiro Miyajima, Toshiro Niki, Hiroki Takahashi, Atsushi Watanabe, Yuji Sakuma · 2019 · Lung Cancer
  12. Fibroblast growth factor receptor 1 inhibition suppresses pancreatic cancer chemoresistance and chemotherapy-driven aggressiveness
    Qingxiang Lin, Andrea Serratore, Jin Niu, Shichen Shen, Tista Roy Chaudhuri, Wen Wee Ma, Jun Qu, Eugene Kandel, Robert M. Straubinger · 2024 · Drug Resistance Updates
  13. Functional diagnostics using fresh uncultured lung tumor cells to guide personalized treatments
    Sarang S. Talwelkar, Mikko Ilari Mäyränpää, Lars Søraas, Swapnil Potdar, Jie Bao, Annabrita Hemmes, Nora Linnavirta, Jon Lømo, Jari Veli Räsänen, Aija Knuuttila et al. · 2021 · Cell Reports Medicine
  14. Trametinib downregulates survivin expression in RB1-positive KRAS -mutant lung adenocarcinoma cells
    Toshiyuki Sumi, Sachie Hirai, Miki Yamaguchi, Yusuke Tanaka, Makoto Tada, Toshiro Niki, Hiroki Takahashi, Yuji Sakuma · 2018 · Biochemical and Biophysical Research Communications
  15. Drug–drug conjugates of MEK and Akt inhibitors for RAS-mutant cancers
    Hikaru Fujita, Sachiko Arai, Hiroshi Arakawa, Kana Hamamoto, Toshiyuki Kato, Tsubasa Arai, Nanaka Nitta, Kazuki Hotta, Natsuko Hosokawa, Takako Ohbayashi et al. · 2023 · Bioorganic & Medicinal Chemistry
  16. Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations
    Seyed Saeed Pairawan, Argun Akçakanat, Scott Kopetz, Coya Tapia, Xiaofeng Zheng, Huiqin Chen, Min Jin Ha, Yasmeen Q. Rizvi, Vijaykumar R. Holla, Jing Wang et al. · 2022 · Scientific Reports
  17. Dual inhibition of MEK and p38 impairs tumor growth in KRAS‑mutated non‑small cell lung cancer
    Noriaki Sunaga, Yosuke Miura, Yusuke Tsukagoshi, Norimitsu Kasahara, Tomomi Masuda, Reiko Sakurai, Kyoichi Kaira, Takeshi Hisada · 2019 · Oncology Letters
  18. Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify Kras -Mutant Lung Cancers
    Sarang S. Talwelkar, Ashwini Sakrepatna Nagaraj, Jennifer R. Devlin, Annabrita Hemmes, Swapnil Potdar, Elina A. Kiss, Pipsa Saharinen, Kaisa Salmenkivi, Mikko Ilari Mäyränpää, Krister Wennerberg et al. · 2019 · Molecular Cancer Therapeutics
  19. Primary Cilia Are Frequently Present in Small Cell Lung Carcinomas but Not in Non–Small Cell Lung Carcinomas or Lung Carcinoids
    Kazuya Shinmura, Hisami Kato, Hideya Kawasaki, Takahiko Hariyama, Kimio Yoshimura, Kazuo Tsuchiya, Hirofumi Watanabe, Isao Ohta, Eri Asahina, Fumiya Sumiyoshi et al. · 2023 · Laboratory Investigation
  20. Treatment outcome of NSCLC patients with BRAF mutations: a retrospective, multicentre analysis within the national Network Genomic Medicine (nNGM) Lung Cancer in Germany
    Cornelia Kropf-Sanchen, Anna Rasokat, Petros Christopoulos, Carina Wenzel, Thomas Wehler, M. Rost, Jonas Kulhavy, Niels Reinmuth, Christian Klaus Jochen Schulz, Matthias Scheffler et al. · 2025 · ESMO Open
  21. Enhancing the Therapeutic Efficacy of KRASG12C Inhibitors in Lung Adenocarcinoma Cell Models by Cotargeting the MAPK Pathway or HSP90
    Ying Liu, Lei Wu, Hong Lü, En Wu, Jun Ni, Xiaorong Zhou · 2021 · Journal of Oncology
  22. Predictive biomarkers for response to trametinib in non-small cell lung cancer
    Palak R. Parekh, Gregory M. Botting, Denise B. Thurber, Marika Boruszczak, William Murphy, Greg P. Bertenshaw · 2022 · Tumor Biology
  23. Reprogramming tumor-associated macrophages: The role of MEK-STAT3 inhibition in lung cancer
    Sushama Rawat, Ehssan H. O. Moglad, Muhammad Afzal, Ahsas Goyal, R Roopashree, Pooja Bansal, Shivang Mishra, G.V. Siva Prasad, Atreyi Pramanik, Sami Ibrahim Alzarea et al. · 2024 · Pathology - Research and Practice
  24. Rab8 and Rabin8-Mediated Tumor Formation by Hyperactivated EGFR Signaling via FGFR Signaling
    Jung Hwa Choi, Jee Young Sung, Saerom Lee, Jungyoen Yoo, Christopher Rongo, Yong-Nyun Kim, Jaegal Shim · 2020 · International Journal of Molecular Sciences
  25. Targeting KRASG12C Mutation: Development of effective strategies to overcome drug resistance and limited efficacy
    Rui Li, Xu Huang, Rui Wang, Zhenhua Ren, Yong Lian Zhu, Tao Lu, Yan Sun, Cui Hao · 2025 · European Journal of Medicinal Chemistry
  26. Targeted inhibition of NRF2 reduces the invasive and metastatic ability of HIP1 depleted lung cancer cells
    Peeyush Prasad, Jonita Chongtham, S. C. Tripathi, Nirmal Kumar Ganguly, Shivani Arora Mittal, Tapasya Srivastava · 2024 · Biochemical and Biophysical Research Communications
  27. p38 mitogen-activated protein kinase inhibitors
    Ashraf Kareem El‐Damasy, Mohamed S. H. Salem, Mahmoud M. Sebaiy, Mohamed Saleh Elgawish · 2024 · Elsevier eBooks
  28. DNA methylation-mediated FGFR1 silencing enhances NF-κB signaling: implications for asthma pathogenesis
    Minglu Meng, Yingjiao Ma, Jianguo Xu, Gao Chen, Roshan Kumar Mahato · 2024 · Frontiers in Molecular Biosciences
  29. Mechanisms of Adaptive Resistance to Targeted Therapy in RET -Aberrant Cancers
    Sandra Ortiz‐Cuaran, Camille Léonce · 2025 · Clinical Cancer Research
  30. The FGFR inhibitor pemigatinib overcomes cancer drug resistance to KRAS G12C inhibitors in mesenchymal lung cancer
    Angela Abdollahi, Margaret F. Favata, Michael Weber, Valerie Dostalik Roman, Rodrigo Hess, Kayla Hammond, Matthew R. Farren, Mike Schaffer, Aidan G. Gilmartin, Hui Wang et al. · 2025 · PLoS ONE
  31. Cetuximab co-treatment with KRAS G12C inhibitors fulzerasib and sotorasib in human KRAS G12C non-small cell lung cancer cells
    Daniel Olmo-González, Mengxin Zhou, Nuno G. Oliveira, Fusheng Zhou, Feng Yan, Jèssica González, Kevin València-Clua, Miguel Ángel Molina‐Vila, Jordi Bertrán-Alamillo, Ana A. Giménez-Capitán et al. · 2026 · Cell Death Discovery
  32. Tobacco Smoke Condensate Induces Morphologic Changes in Human Papillomavirus-Positive Cervical Epithelial Cells Consistent with Epithelial to Mesenchymal Transition (EMT) with Activation of Receptor Tyrosine Kinases and Regulation of TGFB
    Zaniya A. Mark, Linda Chia‐Hui Yu, Lysandra Castro, Xiaohua Gao, Noelle R. Rodriguez, Deloris Sutton, Erica Scappini, Charles J. Tucker, Robert N. Wine, Yitang Yan et al. · 2024 · International Journal of Molecular Sciences
  33. ASCL1-ERK1/2 Axis: ASCL1 restrains ERK1/2 via the dual specificity phosphatase DUSP6 to promote survival of a subset of neuroendocrine lung cancers
    Ana Martín-Vega, Svetlana A. Earnest, Alexander Augustyn, Chonlarat Wichaidit, Adi F. Gazdar, Luc Girard, Michael Peyton, Rahul Krishna Kollipara, John Dorrance Minna, Jane E. B. Johnson et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  34. Epithelial to Mesenchymal Transition (EMT)
    Rishabha Malviya, Arun Kumar Singh, Deepika Yadav · 2023
  35. Disrupting the KRAS–SOS1 protein–protein interaction: mechanistic rationale for pan-KRAS pathway suppression and combination therapy
    Emadeldin M. Kamel, Sally Mostafa Khadrawy, Mohamed A. M. Ali, Mostafa R. Abukhadra, Nour Y. S. Yassin, Saleh Alkhedhairi, Faris F. Aba Alkhayl, Al Mokhtar Lamsabhi · 2026 · Frontiers in Chemistry
  36. Tumor‐Selective Gene Therapy: Using Hairpin DNA Oligonucleotides to Trigger Cleavage of Target RNA by Endogenous flap endonuclease 1 (FEN 1) Highly Expressed in Tumor Cells
    Chunlu Wang, Chen Wang, Chenxin Xiao, Weijie Zhang, Yan Hua Guo, Ming Qu, Qinxin Song, Xiaole Qi, Bingjie Zou · 2025 · Small
  37. Furin-like enzyme dependency in KRAS-mutant colorectal cancer as a target for personalized treatment strategies
    Géraldine Siegfried, Yiyang Liu, Zongcheng He, Serge Évrard, Iker Badiola, Simon Pernot, John W.M. Creemers, Abdel‐Majid Khatib · 2026 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
  38. Sensitivity and Resistance to BH3 Mimetics in Cancer Therapy
    Konstantinos V. Floros, Anthony C. Faber, Hisashi Harada · 2018 · Resistance to targeted anti-cancer therapeutics
  39. KRAS combination strategies: How well aligned is clinical and preclinical research?
    Ernest Nadal, Chiara Ambrogio, David Santamarı́a, Colin R. Lindsay · 2024 · Elsevier eBooks
  40. Mesenchymal tumor cells drive adaptive resistance of Trp53−/− breast tumor cells to inactivated mutant Kras
    Linda J. van Weele, Sabra I. Djomehri, Shang Cai, Jane Antony, Shaheen S. Sikandar, Dalong Qian, William Hai Dang Ho, Robert B. West, Ferenc A. Scheeren, Michael F. Clarke · 2022 · Molecular Oncology
  41. Inhibition of MEK, a canonical KRAS pathway effector in KRAS mutant NSCLC
    Rafael Rosell, Niki Karachaliou, Carles Codony, Masaoki Ito · 2018 · Translational Lung Cancer Research
  42. FGFR2 fusion protein-driven mouse models of intrahepatic cholangiocarcinoma unveil a necessary role for Erk signaling
    Giulia Cristinziano, Manuela Porru, Dante Lamberti, Simonetta Buglioni, Francesca Rollo, Carla Azzurra Amoreo, Isabella Manni, Diana Giannarelli, Cristina Cristofoletti, Giandomenico Russo et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  43. Identifying commonalities between cell lines and tumors at the single cell level using Sobolev Alignment of deep generative models
    Soufiane M. C. Mourragui, Joseph C. Siefert, Marcel J. T. Reinders, Marco Loog, Lodewyk F.A. Wessels · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  44. MEK inhibitor resistance in lung cancer cells associated with addiction to sustained ERK suppression
    Dylan Farnsworth, Yusuke Inoue, Fraser D. Johnson, Georgia de Rappard-Yuswack, Daniel Lu, Rocky Shi, Romel Somwar, Marc Ladanyi, Arun M. Unni, William Wirt Lockwood · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  45. Unravelling Lung Cancer Heterogeneity and Associated Therapeutic Responses using in vivo and ex vivo Model Systems
    Ashwini Sakrepatna Nagaraj · 2018 · Työväentutkimus Vuosikirja
  46. Development of an adenosquamous carcinoma histopathology-selective lung cancer graft model
    Iris A.K. Lähdeniemi, Jennifer R. Devlin, Ashwini Sakrepatna Nagaraj, Sarang S. Talwelkar, Ji Bao, Nora M Linnavirta, C. Şeref Vujaklija, Elina A. Kiss, Annabrita Hemmes, Emmy W. Verschuren · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  47. Development of an adenosquamous carcinoma histopathology – selective lung metastasis model
    Iris A.K. Lähdeniemi, Jennifer R. Devlin, Ashwini Sakrepatna Nagaraj, Sarang S. Talwelkar, Jie Bao, Nora Linnavirta, Ceren Şeref, Elina A. Kiss, Annabrita Hemmes, Emmy W. Verschuren · 2022 · Biology Open
  48. Huntingtin Interacting Protein-1 expression is regulated via HIF2 axis in Lung Adenocarcinoma
    Peeyush Prasad, Jonita Chongtham, S. C. Tripathi, Nirmal Kumar Ganguly, Shivani Arora Mittal, Tapasya Srivastava · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  49. Single-Cell RNA and ATAC Sequencing Reveal Cellular Heterogeneity and Chromatin Accessibility Dynamics in Young Chinese Breast Cancer Patients across Pre- and Post-Neoadjuvant Therapy
    Xue Mei Han, Bin Wang, Wenting Xiang, Fan Yu Lin, Bo Sun, Beibei Yang, Zhihan Ruan, Shasha Liu, Shuo Li, Hong Shu Liu et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  50. Leveraging death of drug-sensitive cancer cells to promote immune-mediated bystander killing of subclones of drug-resistant tumour cells
    Mona Tomaschko, KangBo Ng, Christopher Moore, Claire E. Pillsbury, Sareena Rana, James Campbell, Saptaparna Mukherjee, Ania Mikolajczak, Panayiotis Anastasiou, Andrea de Castro et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  51. Genetic composition and evolutionary trajectories of brain metastasis in non-small-cell lung cancer
    Marcin Nicoś, Natalia Galant, Anna Kowalczyk, Rafał Pęksa, Bożena Jarosz, Monika Żuk, Bartosz Wasąg, Renata Duchnowska, Paweł Krawczyk, Jacek Jassem et al. · 2025 · Lung Cancer
  52. MECP2- Dependent Cancers Can Be Targeted by Epigenetic Drugs: A New Role for Epigenetic Cancer Therapy
    Manish Neupane, Mukesh Kumar, Malela A Mwamufiya, Colleen M. Donnelly, Alsu Ibragimova, Brian Curcio, Inna Chervoneva, Irina A. Vasilevskaya, Daniel P. Silver · 2025 · Molecular Cancer Therapeutics
  53. MAPK pathway modulation and its implications in KRAS mutant lung adenocarcinoma
    Sergio de Hita Román · 2023 · theses.fr (ABES)
  54. Unlocking drug sensitivity in KRAS
    MingCong LI, YueSong ZHOU, Tai Dong Qiao, QingLin BAI, Chuanchuan Li · 2026 · Scientia Sinica Vitae
  55. Current Status and Prospects of Combination Drug and Its Artificial Intelligence Algorithm Development
    Rui Li, Lanxin Long, Ruidi Zhu, Chengwei Wu, Jian Zhang · 2026 · 中国科学基金
  56. Preclinical and clinical evaluation of futibatinib in combination with binimetinib in patients with advanced cancer
    Jordi Ahnert Rodon, Bert H. O’Neil, Christopher Lim, Natraj Reddy Ammakkanavar, Carlos Torrado, Kazuaki Matsuoka, Hiroshi Hirai, Akihiro Miura, Bailey Anderson, Leah Jin et al. · 2026 · Investigational New Drugs
  57. KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones
    Mona Tomaschko, KangBo Ng, Christopher L. Moore, Claire E. Pillsbury, Sareena Rana, James Campbell, Saptaparna Mukherjee, Anna Mikolajczak, Panayiotis Anastasiou, Andrea de Castro et al. · 2026 · Cancer Research
  58. Targeting ATF3-mediated asparagine biosynthesis reverses acquired resistance to KRASG12C inhibitors
    Yanjing Zhu, Chi Zhang, Min Li, Luoyan Ai, Fan Xu, Yiyi Yu, Shan Yu, Xiaojing Xu, Qing Liu, Mengxuan Zhu et al. · 2026 · Oncogene
  59. The role of homeobox genes in signaling pathway positive feedback loops and cancer therapy
    Ben Zion Vider · 2026 · Frontiers in Oncology
  60. Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C–mutant non-small cell lung cancer
    Liu Yifeng, Shigeki Nanjo, Yuya Murase, Sachiko Arai, Satoshi Watanabe, Takeshi Tsuda, Junya Suzuki, Hirokazu Taniguchi, Kazuhiko Shibata, Shigeki Sato et al. · 2026 · Oncogene
  61. A biological-response compound representation allows chemical perturbation prediction across cell lines
    Léa Kaufmann, Lola Le Breton, Elise Carraz-Billat, Quentin Fournier, Sébastien Lemieux · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  62. BindingDB Entry 50021765: Drug-drug conjugates of MEK and Akt inhibitors for RAS-mutant cancers.
    BindingDB · 2025 · UC San Diego